Literature DB >> 567032

Treatment of idiopathic thrombocytopenic purpura in adults. Long-term results in a series of 41 patients.

E Ikkala, E Kivilaakso, M Kotilainen, J Hästbacka.   

Abstract

The results of treatment of idiopathic thrombocytopenic purpura (ITP) were analysed in a series of 41 patients 2 to 10 years (median 4 years) after initial treatment. There was one spontaneous remission. A good or fair long-term result was obtained in 11 patients after prednisone treatment, in 20 of 24 patients after splenectomy, and in 3 of 4 patients after immunosuppressive treatment. Short duration of symptoms and rapid response to prednisone had some value in predicting a good long-term result of prednisone treatment. Young age, a good response to prednisone and splenic sequestration of platelets were associated with good results after splenectomy, as was rapid postoperative normalization of platelet counts. These factors were unable to disclose with certainty a refractoriness to splenectomy. Nevertheless splenectomy was regarded to be the treatment of choice in all patients not adequately controlled with corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 567032

Source DB:  PubMed          Journal:  Ann Clin Res        ISSN: 0003-4762


  3 in total

Review 1.  Current concepts in the treatment of immune thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Surgical treatment of immune thrombocytopenic purpura.

Authors:  P Chirletti; M Cardi; P Barillari; A Vitale; P Sammartino; A Bolognese; R Caiazzo; M Ricci; I A Muttillo; V Stipa
Journal:  World J Surg       Date:  1992 Sep-Oct       Impact factor: 3.352

3.  Spontaneous bilateral peripapillary, subhyaloid and vitreous hemorrhage with only minor platelet deficit in idiopathic thrombocytopenic purpura.

Authors:  Loo Wan-Wei; Tuan-Jaffar Tengku-Norina; Ahmad-Alwi Azma-Azalina; Abdul-Ghani Zulkifli; Embong Zunaina
Journal:  Int Med Case Rep J       Date:  2014-01-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.